NY-ESO expression in osteosarcoma (490P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Piotr Rutkowski

Citation

Annals of Oncology (2017) 28 (suppl_10): x149-x152. 10.1093/annonc/mdx675

Authors

I. Lugowska1, T. Klepacka2, A. Szumera-Cieckiewicz3, E. Michalak2, M. Lenarcik3, A. Pienkowski4, P. Teterycz4, K. Szamotulska5, P. Rutkowski4

Author affiliations

  • 1 Soft Tissue/bone Sarcoma And Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw/PL
  • 2 Pathology, Institute of Mother and Child, Warsaw/PL
  • 3 Pathology, Maria Sklodowska-Curie Institute - Oncology Center, 02781 - Warsaw/PL
  • 4 Soft Tissue/bone Sarcoma And Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, 02781 - Warsaw/PL
  • 5 Biostatistics, Institute of Mother and Child, Warsaw/PL
More

Resources

Background

New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is a cancer-testis antigen expressed in normal tissue (male germ cells), as well as in breast, or lung cancers, hepatocellular carcinomas, melanomas, or soft tissues sarcomas. In early phase clinical trials, NY-ESO-1 is being studied as possible target for a cancer vaccine, immunotherapy, or in experimental engineered T-cell treatment. The aim of this study was to determine the frequency of expression of NY-ESO-1 protein in osteosarcoma patient population, and to correlate NY-ESO-1 expression with clinical outcomes.

Methods

We analysed 160 biopsy samples of osteosarcoma patients (aged 4-65 years; median 15 years; 59 women and 101 men). Twenty eight patients had metastatic disease at presentation, 11 – axial localisation of primary tumour, and all patients received multimodality treatment. Follow-up period was at least 5 years. The expression of NY-ESO was assessed with immunohistochemical staining in pretreatment samples. The cut-off points of NY-ESO-1 expression were 0% and 50%. Univariate analyses were conducted to assess the relationship between NY-ESO-1 expression and clinical outcomes.

Results

NY-ESO-1 expression in osteosarcoma was present in 22.5% cases. The only one significant relationships was found between NY-ESO-1 and clinical stage (localised/dissemination); p = 0.047. There was no other statistically significant relations between NY-ESO-1 and clinical outcomes such as overall survival, progression/disease free survival, patient age, gender, osteosarcoma subtype or its aggressiveness.

Conclusions

Immunotherapeutic strategies to target NY-ESO-1-expressing lesions in osteosarcoma may be addressed to limited proportion patients. There is no data confirming the utility of assessment of NY-ESO-1 as a prognostic factor in osteosarcoma.

Clinical trial identification

Legal entity responsible for the study

Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland

Funding

None

Disclosure

P. Rutkowski: Received honoraria for lectures from Novartis, Roche, Pfizer, BMS, MSD and served as a member of Advisory Board for Novartis, Merck, Amgen, Blueprint, Roche, BMs and MSD.

All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings